Role of SGLT2 Inhibitors in Type 2 Diabetes With Chronic Kidney Disease

Source: Navigating the Latest Options for the Treatment of CKD in T2D
Download Slideset
A leading expert provides an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes.
Jennifer B. Green, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.91 MB
Released: July 12, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings